Myricx Bio

Myricx Bio is a UK-based biotech company specializing in the development of novel antibody-drug conjugates (ADCs) for cancer treatment. The company is headquartered in London and is focused on discovering and developing a completely new class of payloads for ADCs, based on inhibitors of the enzymes N-myristoyltransferases (NMT). NMT is an enzyme that adds a specific lipid modification to a number of protein targets that are key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMTi payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour-associated antigens and cancer cell types.

Myricx Bio was spun out from Imperial College London and the Francis Crick Institute in 2019 and has since raised significant funding from leading life science investors including Novo Holdings, Abingworth, Brandon Capital, and Sofinnova Partners. The company is rapidly expanding its team and has a strong focus on clinical development. Myricx's proprietary NMTi-ADCs have shown promising preclinical results, including complete and durable tumor regressions in multiple cancer models that are refractory to standard-of-care ADCs. The company is committed to developing novel and effective therapies for cancer patients and is poised to become a leading player in the ADC space.

Myricx Bio is a UK biotech company focused on developing a novel class of payloads for antibody drug conjugates (ADCs) based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. The company is committed to addressing serious unmet needs in oncology by developing highly effective and safe ADCs that target clinically validated cancer-associated antigens. Myricx's proprietary NMT inhibitor (NMTi) payload chemistry platform has demonstrated excellent preclinical efficacy and safety across multiple solid tumor types, with the potential to significantly expand the current repertoire of ADC applications and offer new treatment options for patients.

Myricx Bio cultivates a collaborative and innovative culture that values scientific excellence, entrepreneurial spirit, and a strong commitment to developing novel therapies. The company fosters a dynamic environment where diverse perspectives are encouraged, and its team is comprised of internationally renowned scientists and drug hunters with a proven track record of success in both academia and industry. Myricx embraces a culture of open communication, knowledge sharing, and a passion for pushing the boundaries of drug discovery to address unmet needs in oncology.

Myricx Bio is committed to fostering a diverse, equitable, and inclusive work environment where all individuals are valued, respected, and have the opportunity to succeed. They are actively recruiting and retaining talent from a wide range of backgrounds and perspectives, while promoting a culture of belonging, fairness, and respect. Myricx Bio prioritizes creating opportunities for all employees to learn and grow, ensuring equitable access to resources and opportunities, and actively combating bias and discrimination in all aspects of the workplace.